Regulatory challenges: Lessons from recent West Nile virus trials in the United States

Contemporary Clinical Trials

Volumn 27, Issue 3, 2006, Pages 254-259

  Jester, Penelope M ^a   Tilden, Samuel J ^a,b   Li, Yufeng ^a,c   Whitley, Richard J ^a,c,d   Sullender, Wayne M ^a,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Institutional Review Board; Protocol development; West Nile virus

Indexed keywords

ARTICLE; CLINICAL RESEARCH; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE ORGANIZATION; HUMAN; METHODOLOGY; UNITED STATES; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

CLINICAL PROTOCOLS; CLINICAL TRIALS; DISEASE PROGRESSION; ETHICS COMMITTEES, RESEARCH; HUMANS; INCIDENCE; MULTICENTER STUDIES; SEASONS; TIME FACTORS; UNITED STATES; WEST NILE FEVER;

EID: 33646168992     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2006.02.004     Document Type: Article

References (18)

1. Burman W., Breese P., Weis S., et al. The effects of local review on informed consent documents from a multicenter clinical trials consortium.[see comment]. Control Clin Trials 24 (2003) 245-255
2. Stair T.O., Reed C.R., Radeos M.S., Koski G., Camargo C.A., and Collaboration MIMAR. Variation in institutional review board responses to a standard protocol for a multicenter clinical trial. Acad Emerg Med 8 (2001) 636-641
3. McWilliams R., Hoover-Fong J., Hamosh A., et al. Problematic variation in local institutional review of a multicenter genetic epidemiology study.[see comment]. JAMA 290 (2003) 360-366
4. Mosesso Jr. V.N., Brown L.H., Greene H.L., et al. Conducting research using the emergency exception from informed consent: the Public Access Defibrillation (PAD) Trial experience. Resuscitation 61 (2004) 29-36
5. 21 UCS 355(i) (2), 21 CFR 312.40(b).
6. Petersen L., and Marfin A. West Nile virus: a primer for the clinician. Ann Intern Med 137 (2002) 173-179
7. Centers for Disease Control and Prevention, National Centers for Disease Control and Prevention and Diseases NCfI. Epidemic/Epizootic West Nile virus in the United States: Guidelines for surveillance, prevention and control. Fort Collins, CO. 3rd revision. 2003:22.
8. 21 CFR 312.40(1).
9. 21 CFR 312.20 (c).
10. 021 USC §360bbb-3.
11. Loh E.D., and Meyer R.E. Medical schools' attitudes and perceptions regarding the use of central institutional review boards. Acad Med 79 (2004) 644-651
12. Burman W.J., Reves R.R., Cohn D.L., and Schooley R.T. Breaking the camel's back: multicenter clinical trials and local institutional review boards.[see comment]. Ann Intern Med 134 (2001) 152-157
13. Emanuel E.J., Wood A., Fleischman A., et al. Oversight of human participants research: identifying problems to evaluate reform proposals. Ann Intern Med 141 (2004) 282-291
14. Whitley R. 'Fast Track' research. Wall Street J (June 19, 2003)
15. Reed K.D., Melski J.W., Graham M.B., et al. The detection of monkeypox in humans in the Western Hemisphere. [see comment]. N Engl J Med 350 (2004) 342-350
16. Poutanen S.M., Low D.E., Henry B., et al. Identification of severe acute respiratory syndrome in Canada. [see comment]. N Engl J Med 348 (2003) 1995-2005
17. Cyranoski D. Critics slam treatment for SARS as ineffective and perhaps dangerous. Nature 423 (2003) 4
18. Beck R.W. The office for human research protections and the NIH. (Letter). N Engl J Med 349 (2003) 2076-2077